NeuroSense Therapeutics Ltd. (NRSN) Form 6-K — Oct 2, 2026
NeuroSense Therapeutics (NASDAQ: NRSN) received a Nasdaq Staff Determination on October 1, 2026 stating it has not regained compliance with the $35 million minimum market value requirement, putting its ordinary shares and warrants at risk of delisting. The Company will appeal by requesting a Nasdaq Hearings Panel hearing, which stays any delisting pending the Panel's decision; the Panel can grant up to 180 days of exception time. Meanwhile, shares should continue trading under NRSN and NRSNW. Separately, NeuroSense regained compliance with the $1.00 minimum bid price rule after its 1-for-20 reverse split, with the bid above $1.00 for 10 consecutive business days from September 15-28, 2026.
Key figures
- Reverse split ratio
- 1:20
- Mvls requirement usd
- $35 million
- Minimum bid price usd
- 1
- Compliance days granted
- 180
- Panel exception max days
- 180
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.